Reducing bone lead content by chelation treatment in chronic lead poisoning: an in vivo X-ray fluorescence and bone biopsy study.
A stained-glass artist with longstanding exposure to lead presented with neuropsychiatric symptoms. He was evaluated before and after chelation treatment by the CaNa2 EDTA lead mobilization test, iliac crest bone lead measurement, and in vivo tibial X-ray fluorescence (XRF). The three methods showed a progressive fall in body lead stores during chelation therapy in association with improvement in symptoms and a fall in blood lead and zinc protoporphyrin levels. In vivo tibial XRF is a safe, rapid, and noninvasive technique for detecting excessive body lead burdens. XRF measurement of bone lead content is a practical method for monitoring the efficacy of therapy as well as for establishing the diagnosis.
Batuman
V
V
Veterans Administration Medical Center, East Orange, New Jersey 07019.
Wedeen
R P
RP
Bogden
J D
JD
Balestra
D J
DJ
Jones
K
K
Schidlovsky
G
G
D001706:Biopsy; D001842:Bone and Bones / Q000032:analysis*; D004492:Edetic Acid / Q000627:therapeutic use*; D006801:Humans; D007854:Lead / Q000032:analysis*; D007855:Lead Poisoning / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013052:Spectrometry, X-Ray Emission
D007854:Lead; D004492:Edetic Acid